All In Biotech

Drug Trial Radar · NCT05382312

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

A Parallel Group, Phase 2A, Randomised, Open Label Treatment Study to Assess the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 Administered as a Two Drug Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin-susceptible Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Jul 26, 2022

Primary completion

May 27, 2025

Study completion May 27, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Click-TB Consortium
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or standard of care, for 14 days, in participants with newly diagnosed sputum smear positive drug-sensitive pulmonary tuberculosis. Participants reverted to the standard treatment (RIFAFOUR e-275) once the study treatment (Day 1 to Day 14) was completed.

Conditions

  • Tuberculosis

Interventions

  • GSK3036656Drug

    GSK3036656 was administered.

  • BedaquilineDrug

    Bedaquiline was administered.

  • DelamanidDrug

    Delamanid was administered.

  • RIFAFOUR e-275Drug

    RIFAFOUR e-275 was administered.

  • BTZ-043Drug

    BTZ-043 was administered.

  • PretomanidDrug

    Pretomanid was administered.

  • LinezolidDrug

    Linezolid was administered.

  • MoxifloxacinDrug

    Moxifloxacin was administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bellville, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.